Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...

Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

On Friday, Wells Fargo (NYSE:WFC) initiated coverage on Sarepta Therapeutics (NASDAQ:SRPT), currently trading at $50.31, assigning an Overweight rating to the biopharmaceutical company with a price ...

NEW YORK, March 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors ...

Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial prospects for Elevidys, a gene therapy developed by SRPT with Roche ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (BMV:SRPT) with a Overweight recommendation. There are 956 funds or institutions reporting positions ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Overweight recommendation. As of April 1, 2025, the average one-year price ...